Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MASS Stock Forecast 2026-2027
$7.16
Current Price
$267.64M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MASS Price Targets
+67.6%
To High Target of $12.00
+39.7%
To Median Target of $10.00
+11.7%
To Low Target of $8.00
MASS Price Momentum
-0.6%
1 Week Change
+17.2%
1 Month Change
+50.4%
1 Year Change
+36.4%
Year-to-Date Change
-23.3%
From 52W High of $9.34
+70.5%
From 52W Low of $4.20
📊 TOP ANALYST CALLS
Did MASS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if 908 Devices is one of their latest high-conviction picks.
Latest MASS Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, MASS has a bullish consensus with a median price target of $10.00 (ranging from $8.00 to $12.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $7.16, the median forecast implies a 39.7% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Puneet Souda at Leerink Partners, projecting a 67.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MASS Analyst Ratings
4
Buy
0
Hold
0
Sell
MASS Price Target Range
Low
$8.00
Average
$10.00
High
$12.00
Current: $7.16
Latest MASS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MASS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 5, 2025 | Leerink Partners | Puneet Souda | Outperform | Upgrade | $12.00 |
| Jan 15, 2025 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $6.00 |
| Nov 13, 2024 | Stifel | Daniel Arias | Buy | Maintains | $6.00 |
| Nov 13, 2024 | Leerink Partners | Puneet Souda | Market Perform | Downgrade | $4.00 |
| Oct 17, 2024 | Leerink Partners | Outperform | Maintains | $12.00 | |
| May 13, 2024 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $14.00 |
| Sep 25, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Reiterates | $14.00 |
| Feb 7, 2023 | Stephens & Co. | Jacob Johnson | Overweight | Initiates | $14.00 |
| Jan 6, 2023 | SVB Leerink | Puneet Souda | Outperform | Maintains | $20.00 |
| Nov 15, 2022 | SVB Leerink | Puneet Souda | Outperform | Maintains | $25.00 |
| Mar 8, 2022 | SVB Leerink | Puneet Souda | Outperform | Maintains | $30.00 |
| May 14, 2021 | SVB Leerink | Puneet Souda | Outperform | Maintains | $65.00 |
| Jan 12, 2021 | Cowen & Co. | Outperform | Initiates | $N/A | |
| Jan 12, 2021 | SVB Leerink | Outperform | Initiates | $N/A | |
| Jan 12, 2021 | Stifel | Buy | Initiates | $N/A |
908 Devices Inc. (MASS) Competitors
The following stocks are similar to 908 Devices based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
908 Devices Inc. (MASS) Financial Data
Valuation Metrics
Market Cap
$267.64M
Enterprise Value
$159.30M
P/E Ratio
N/A
PEG Ratio
-22.9x
Price/Sales
4.8x
Growth & Margins
Revenue Growth (YoY)
-7.7%
Gross Margin
+52.7%
Operating Margin
-17.3%
Net Margin
+34.7%
EPS Growth
-7.7%
Financial Health
Cash/Price Ratio
+42.2%
Current Ratio
4.2x
Debt/Equity
3.2x
ROE
-25.8%
ROA
-9.0%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
908 Devices Inc. (MASS) Business Model
About 908 Devices Inc.
What They Do
Develops innovative chemical analysis devices.
Business Model
908 Devices Inc. creates and sells portable analytical tools for chemical and biochemical analysis. The company generates revenue through the sale of its handheld, desktop, and small-scale instruments that are utilized in various sectors like life sciences, pharmaceuticals, and public safety, catering to applications such as drug development and environmental monitoring.
Additional Information
The company's focus on miniaturizing complex instrumentation allows for real-time, point-of-need analytics, enhancing efficiency and accuracy. This innovative approach positions 908 Devices Inc. as a leader in advancing technology in analytical methodologies, significantly impacting decision-making processes across multiple industries.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
172
CEO
Dr. Kevin J. Knopp Ph.D.
Country
United States
IPO Year
2020
Website
908devices.com908 Devices Inc. (MASS) Latest News & Analysis
Latest News
Quick Summary
908 Devices Inc. (Nasdaq: MASS) will present at the Sidoti Small Cap Conference on March 18, 2026, at 1:45 p.m. ET, with CEO Kevin J. Knopp and CFO Joe Griffith hosting investor meetings.
Why It Matters
908 Devices' participation in the Sidoti Small Cap Conference highlights its growth potential and investor interest, potentially influencing stock performance and market perception.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
908 Devices Inc. (MASS) has released its Q4 2025 earnings call transcript, detailing financial performance and business updates for the quarter.
Why It Matters
The Q4 2025 earnings call provides insights into 908 Devices Inc.'s financial performance, growth prospects, and strategic direction, influencing investor sentiment and stock valuation.
Source: Seeking Alpha
Market Sentiment:
Neutral
908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
1 month ago
Quick Summary
908 Devices Inc. reported Q4 2025 revenue of $17.4 million, a 21% increase from Q4 2024, with full-year revenue at $56.2 million.
Why It Matters
908 Devices Inc. reported a 21% revenue increase in Q4 2025, signaling strong growth potential and market demand, which may attract investor interest and positively impact stock valuation.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
908 Devices Inc. (MASS) reported a quarterly loss of $0.05 per share, better than the expected loss of $0.06, improving from a loss of $0.32 per share a year ago.
Why It Matters
908 Devices' smaller quarterly loss than expected indicates improved financial performance, potentially boosting investor confidence and impacting stock valuation positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
908 Devices Inc. (Nasdaq: MASS) will participate in the TD Cowen Healthcare Conference on March 4 and the Leerink Global Healthcare Conference on March 9 for investor discussions.
Why It Matters
908 Devices' participation in major investor conferences signals potential growth and visibility in the healthcare sector, attracting investor interest and possibly influencing stock performance.
Source: Business Wire
Market Sentiment:
Neutral
908 Devices to Report Fourth Quarter and Full Year 2025 Financial Results on March 3, 2026
2 months ago
Quick Summary
908 Devices Inc. (Nasdaq: MASS) will report its Q4 and full-year 2025 financial results on March 3, 2026, before market open, followed by a conference call at 8:30 a.m. ET.
Why It Matters
The upcoming financial results announcement could significantly impact 908 Devices Inc.'s stock price and investor sentiment, indicating performance trends and future growth potential.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About MASS Stock
What is 908 Devices Inc.'s (MASS) stock forecast for 2026?
Based on our analysis of 4 Wall Street analysts, 908 Devices Inc. (MASS) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $8.00.
Is MASS stock a good investment in 2026?
According to current analyst ratings, MASS has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MASS stock?
Wall Street analysts predict MASS stock could reach $10.00 in the next 12 months. This represents a 39.7% increase from the current price of $7.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is 908 Devices Inc.'s business model?
908 Devices Inc. creates and sells portable analytical tools for chemical and biochemical analysis. The company generates revenue through the sale of its handheld, desktop, and small-scale instruments that are utilized in various sectors like life sciences, pharmaceuticals, and public safety, catering to applications such as drug development and environmental monitoring.
What is the highest forecasted price for MASS 908 Devices Inc.?
The highest price target for MASS is $12.00 from Puneet Souda at Leerink Partners, which represents a 67.6% increase from the current price of $7.16.
What is the lowest forecasted price for MASS 908 Devices Inc.?
The lowest price target for MASS is $8.00 from at , which represents a 11.7% increase from the current price of $7.16.
What is the overall MASS consensus from analysts for 908 Devices Inc.?
The overall analyst consensus for MASS is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are MASS stock price projections?
Stock price projections, including those for 908 Devices Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:19 AM UTC